The logo for AstraZeneca outside its North America headquarters in Wilmington, Del., on Mar. 22, 2021. Rachel Wisniewski/Reuters
AstraZeneca announced on Sept. 29 that it will list its ordinary shares directly on the New York Stock Exchange, replacing its American depository receipts, but said it is not abandoning London.
AstraZeneca, the UK’s second-biggest listed company with a market value of 170 billion pounds ($228 billion), said the change is part of a plan to “harmonise” its listing structure across London, Stockholm, and New York, making it easier for investors to trade its stock globally.
